Adjusting Survival Curves to Incorporate External Evidence: A Simplified Approach without Patient-Level Data

INTRODUCTION: Cost-effectiveness modelling often requires the extrapolation of survival data from clinical trials. The choice of extrapolation method is often uncertain and can have a profound effect on the results. We propose an approach that incorporates external evidence (eg, from published studies, registries, or elicited clinical opinion) into the extrapolation process to reduce uncertainty. This method can be applied to adjust previously fitted parametric curves as a secondary analysis, without access to the underlying patient-level data. Adjusted curves can be easily exported and used in spreadsheet-based models. METHODS: Standard parametric survival curves are fitted to time-to-event data using maximum likelihood estimation (MLE). These are combined with external evidence on expected cohort-level survival at a future time point(s), formulated as a probability distribution, to generate adjusted survival curves that simultaneously incorporate both observed data and external evidence. Parameter estimation uses importance sampling and multivariate normal approximations of the likelihood. We apply our method to a case study of survival extrapolation from immuno-oncology. RESULTS: Our method resulted in extrapolated survival predictions that were more closely aligned with the external evidence compared with the standard (MLE-based) approach. The incorporation of external evidence decreased the between-distribution variance (reduced structural uncertainty) and for most distributions also decreased within-distribution variance (reduced parametric uncertainty). CONCLUSION: Our extrapolation method can reduce uncertainty when valid external evidence is available. Only MLE-based parameter estimates are required to implement our method; thus, secondary model users such as health technology assessment bodies can adjust survival extrapolations from existing cost-effectiveness models without access to patient-level data. Implementation is straightforward and computationally efficient, and outputs are easily incorporated into existing cost-effectiveness models.

Authors

Institutions

Publication Details

Journal
Medical Decision Making
Published
2026-08-25
DOI
https://doi.org/10.1177/0272989x261472806
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjusting Survival Curves to Incorporate External Evidence: A Simplified Approach without Patient-Level Data

Laura McCullagh, Felicity Lamrock, Lea Trela-Larsen, Arthur White et al.
Medical Decision Making
Health Systems, Economic Evaluations, Quality of Life
article

Adjusting Survival Curves to Incorporate External Evidence: A Simplified Approach without Patient-Level Data

Laura McCullagh, Felicity Lamrock, Lea Trela-Larsen, Arthur White, Joy Leahy, J.R. O’Callaghan, David J. McConnell
article en

Abstract

INTRODUCTION: Cost-effectiveness modelling often requires the extrapolation of survival data from clinical trials. The choice of extrapolation method is often uncertain and can have a profound effect on the results. We propose an approach that incorporates external evidence (eg, from published studies, registries, or elicited clinical opinion) into the extrapolation process to reduce uncertainty. This method can be applied to adjust previously fitted parametric curves as a secondary analysis, without access to the underlying patient-level data. Adjusted curves can be easily exported and used in spreadsheet-based models. METHODS: Standard parametric survival curves are fitted to time-to-event data using maximum likelihood estimation (MLE). These are combined with external evidence on expected cohort-level survival at a future time point(s), formulated as a probability distribution, to generate adjusted survival curves that simultaneously incorporate both observed data and external evidence. Parameter estimation uses importance sampling and multivariate normal approximations of the likelihood. We apply our method to a case study of survival extrapolation from immuno-oncology. RESULTS: Our method resulted in extrapolated survival predictions that were more closely aligned with the external evidence compared with the standard (MLE-based) approach. The incorporation of external evidence decreased the between-distribution variance (reduced structural uncertainty) and for most distributions also decreased within-distribution variance (reduced parametric uncertainty). CONCLUSION: Our extrapolation method can reduce uncertainty when valid external evidence is available. Only MLE-based parameter estimates are required to implement our method; thus, secondary model users such as health technology assessment bodies can adjust survival extrapolations from existing cost-effectiveness models without access to patient-level data. Implementation is straightforward and computationally efficient, and outputs are easily incorporated into existing cost-effectiveness models.

Medical Decision Making
Queen's University Belfast (GB), Trinity College Dublin (IE), National Centre for Pharmacoeconomics (IE), St. James's Hospital (IE)
Openalex Percentile: Top 4%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.